Biology Reference
In-Depth Information
high-density reverse-phase lysate microarrays. Proc
Natl Acad Sci USA 2003;100:14229 e 34.
75. Olle EW, Messamore J, Deogracias MP, et al.
Comparison of antibody array substrates and the use
of glycerol to normalize spot morphology. Exp Mol
Pathol 2005;79:206 e 9.
76. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse
phase protein microarrays which capture disease
progression show activation of pro-survival pathways
at the cancer invasion front. Oncogene 2001;20:1981 e 9.
77. Pawlak M, Schick E, Bopp MA, Schneider MJ,
Oroszlan P, Ehrat M. Zeptosens
88. Sboner A, Karpikov A, Chen G, et al. Robust-linear-
model normalization to reduce technical variability in
functional protein microarrays. J Proteome Res 2009;8:
5451 e 64.
89. Schena M, Shalon D, Davis RW, et al. Quantitative
monitoring of gene expression patterns with a comple-
mentary DNA microarray. Science 1995;270:467 e 70.
90. Shankavaram UT, Reinhold WC, Nishizuka S, et al.
Transcript and protein expression pro
les of the NCI-
60 cancer cell panel: an integromic microarray study.
Mol Cancer Ther 2007;6:820 e 32.
91. Sheehan KM, Calvert VS, Kay EW, et al. Use of reverse
phase protein microarrays and reference standard
development for molecular network analysis of
metastatic ovarian carcinoma. Mol Cell Proteomics
2005;4:346 e 55.
92. Silvestri A, Colombatti A, Calvert VS, et al. Protein
pathway biomarker analysis of human cancer reveals
requirement for upfront cellular-enrichment process-
ing. Lab Invest 2010;90:787 e 96.
93. Spruessel A, Steimann G, Jung M, et al. Tissue
ischemia time affects gene and protein expression
patterns within minutes following surgical
protein microarrays:
a novel high performance microarray platform for low
abundance protein analysis. Proteomics 2002;2:383 e 93.
78. Petricoin III EF, Espina V, Araujo RP, et al. Phospho-
protein pathway mapping: Akt/mammalian target of
rapamycin activation is negatively associated with
childhood rhabdomyosarcoma survival. Cancer Res
2007;67:3431 e 40.
79. Petricoin EF, Bichsel V, Calvert V, et al. Mapping
molecular networks using proteomics: a vision for
patient-tailored combination therapy.
'
J Clin Oncol
2005;23:3614 e 21.
80. Pierotti MA, Negri T, Tamborini E, et al. Targeted ther-
apies: the rare cancer paradigm. Mol Oncol 2010;4:19 e 37.
81. Pirnia F, Pawlak M, Thallinger GG, et al. Novel
functional pro
tumor
excision. Biotechniques 2004;36:1030 e 7.
94. Spurrier B, Ramalingam S, Nishizuka S. Reverse-
phase protein lysate microarrays for cell signaling
analysis. Nat Protoc 2008;3:1796 e 808.
95. Srinivasan M, Sedmak D, Jewell S. Effect of
ling approach combining reverse
phase protein microarrays and human 3-D ex vivo
tissue cultures: expression of apoptosis-related
proteins in human colon cancer. Proteomics 2009;9:
3535 e 48.
82. Popova T, Espina V, Bailey C, et al. Anthrax infection
inhibits the AKT signaling involved in the E-cadherin-
mediated adhesion of lung epithelial cells. FEMS
Immunol Med Microbiol 2009;56:129 e 42.
83. Posadas EM, Simpkins F, Liotta LA, et al. Proteomic
analysis for the early detection and rational treatment
of cancer d realistic hope? Ann Oncol 2005;16:16 e 22.
84. Ramaswamy A, Lin E, Chen I, et al. Application of
protein lysate microarrays to molecular marker veri-
fixatives
and tissue processing on the content and integrity of
nucleic acids. Am J Pathol 2002;161:1961 e 71.
96. Srivastava M, Eidelman O, Zhang J, Stillman BA,
Tonkinson JL. FAST slides: a novel surface for micro-
arrays. Biotechniques 2000;29:630 e 5.
97. Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array:
validation of a novel proteomic technology and utility
for analysis of primary leukemia specimens and hema-
topoietic stem cells. Mol Cancer Ther 2006;5:2512 e 21.
98. Tonkinson JL, Stillman BA. Nitrocellulose: a tried and
true polymer
finds utility as a post-genomic substrate.
Front Biosci 2002;7:c1 e 12.
99. vanOostrumJ, Calonder C, Rechsteiner D, et al. Tracing
pathway activities with kinase inhibitors and reverse
phase protein arrays. Proteomics Clin Appl 2009;3(4):
412 e 22.
100. VanMeter AJ, Rodriguez AS, Bowman ED, et al. Laser
capture microdissection and protein microarray anal-
ysis of human non-small cell lung cancer: differential
epidermal growth factor receptor (EGFR) phosphory-
lation events associated with mutated EGFR compared
with wild type. Mol Cell Proteomics 2008;7:1902 e 24.
101. Voshol H, Ehrat M, Traenkle J, et al. Antibody-based
proteomics: analysis of signaling networks using
reverse protein arrays. FEBS J 2009;276:6871 e 9.
fication Proteome Sci 2005;3:9.
85. Rapkiewicz A, Espina V, Zujewski JA, et al. The nee-
dle in the haystack: application of breast
fication and quanti
fine-needle
aspirate samples to quantitative protein microarray
technology. Cancer 2007;111:173 e 84.
86. Ressine A, Corin I, Jaras K, et al. Porous silicon
surfaces: a candidate substrate for reverse protein
arrays in cancer biomarker detection. Electrophoresis
2007;28:4407 e 15.
87. Romeo MJ, Wunderlich J, Ngo L, et al. Measuring
tissue-based biomarkers by immunochromatography
coupled with reverse-phase lysate microarray. Clin
Cancer Res 2006;12:2463 e 7.
Search WWH ::




Custom Search